zacks.com
Medifast (MED) Down 5.7% Since Last Earnings Report: Can It Rebound?
Medifast (MED) reported earnings 30 days ago. What's next for the stock?
Medifast, Inc.MEDNYSE
Loading
Latest News
Loading news...
businesswire.com
Scientific Evidence Demonstrates OPTAVIA®'s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients
BALTIMORE--(BUSINESS WIRE)--As part of its continued focus on improving metabolic health, Medifast® (NYSE: MED) today announced that OPTAVIA's comprehensive metabolic health system is available for reimbursement on select insurance plans using Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). OPTAVIA clients may be able to save up to 40% on program costs by working with their medical provider and insurance administrator to use pre-tax medical funds, offering accessibility for.
defenseworld.net
Medifast Q4 Earnings Call Highlights
Medifast (NYSE: MED) reported fourth-quarter and full-year 2025 results while outlining continued efforts to reposition the business around metabolic health, highlighting early signs of improving coach productivity even as revenue and the active earning coach base declined sharply. Leadership transition and strategic focus Chairman and CEO Dan Chard said he plans to step down as chief
zacks.com
Medifast Q4 Loss Wider Than Expected, Revenues Decline 37% Y/Y
MED posts a wider quarterly loss as revenue tumbles 36.9% on a sharp drop in OPTAVIA coaches, despite beating revenue estimates.
zacks.com
Medifast (MED) Reports Q4 Loss, Beats Revenue Estimates
Medifast (MED) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to earnings of $0.1 per share a year ago.
seekingalpha.com
Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript
Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript
businesswire.com
Medifast Announces Fourth Quarter and Full Year 2025 Financial Results
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Revenue of $75.1 million, with revenue per active earning coach of $4,664 Independent active earning coaches of 16,100 Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valua.
zacks.com
Medifast's Q4 Earnings on Deck: What Could Shape MED's Results?
MED is likely to post a sharp Q4 revenue drop and a wider loss as active earning coaches decline and GLP-1 pressure weighs despite retention and pricing efforts.
zacks.com
Analysts Estimate Medifast (MED) to Report a Decline in Earnings: What to Look Out for
Medifast (MED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
defenseworld.net
Medifast (MED) to Release Earnings on Tuesday
Medifast (NYSE: MED - Get Free Report) will likely be issuing its Q4 2025 results after the market closes on Tuesday, February 17th. Analysts expect Medifast to post earnings of ($0.80) per share and revenue of $71.40 million for the quarter. Individuals are encouraged to explore the company's upcoming Q4 2025 earning overview page for the
seekingalpha.com
Medifast Is A Net-Net With Negative Enterprise Value
Medifast trades below net cash, with an EV of -$43.68M, reflecting deep skepticism about its OPTAVIA MLM business and turnaround prospects. GLP-1 drugs have rendered MED's weight-loss model largely obsolete, prompting a pivot toward metabolic health services, though execution risk remains high. Despite ongoing losses, MED's cash burn is modest; even with conservative assumptions, shares likely remain a net-net with limited downside over the next year.
businesswire.com
Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2025
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter and full year ended December 31, 2025 on Tuesday, February 17, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney.
zacks.com
Medifast's Q4 Guidance Remains Weak: When Does Growth Return?
MED sees weak Q4 guidance after steep revenue declines, but a metabolic health pivot targets stabilization and recovery.
prnewswire.com
The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings
/PRNewswire/ -- The global consumer healthcare market is hitting a massive structural wall, projected to reach $362.17 billion in 2026[1]. In this high-stakes
businesswire.com
People Magazine Spotlights Tiffany Howard's Metabolic Health Journey with OPTAVIA®
BALTIMORE--(BUSINESS WIRE)--Medifast® (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system OPTAVIA, celebrates the inspiring health transformation of Tiffany Howard, recently featured in People magazine. Tiffany's journey highlights how OPTAVIA's comprehensive program, which combines science-backed nutrition, personalized coaching and sustainable habit-building, reversed her metabolic dysfunction1. For Tiffany, this meant several meaningful he.
businesswire.com
OPTAVIA® Premieres Second Docuseries Episode “Health by Design: Spain” Exploring Metabolic Health and Longevity
BALTIMORE--(BUSINESS WIRE)--Medifast® (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system OPTAVIA, premiered its newest docuseries episode, “Health by Design: Spain”, which explores the cultural, environmental, and community-driven factors promoting long, healthy lives. The second installment in the “Health by Design” series transports viewers to Galicia and Madrid, Spain – spotlighting Galicia, a region renowned for its potential to become t.
zacks.com
Medifast Shifts to Metabolic Health: A Durable Growth Path?
MED is pivoting to metabolic health, using clinical data and new products to address root causes beyond GLP-1 weight loss.
businesswire.com
Medifast Announces Planned Leadership Transition
BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health. Medifast Chairman & Chief Executive Officer Dan Chard has informed the Board of Directors that he plans to step down as Chief Executive Officer in June 2026. Chard will continue to serve as Chairman of the Board following the transition. The Board has appointed Medifast's Chief Fiel.
zacks.com
Medifast New Product Line Planned: Can Innovation Reignite Demand?
MED plans a new product line rooted in metabolic synchronization science, upgrading its core offerings as it shifts beyond weight loss.
zacks.com
Medifast's Third-Quarter Revenue Fell 36%: Is Stabilization Near?
MED witnesses revenue plunge as its coach base shrank, but restructuring and productivity initiatives aim to stabilize results by late 2025.